DE69430816D1 - Verwendung von Piperidin-Derivaten in der Behandlung von Schizophrenie - Google Patents

Verwendung von Piperidin-Derivaten in der Behandlung von Schizophrenie

Info

Publication number
DE69430816D1
DE69430816D1 DE69430816T DE69430816T DE69430816D1 DE 69430816 D1 DE69430816 D1 DE 69430816D1 DE 69430816 T DE69430816 T DE 69430816T DE 69430816 T DE69430816 T DE 69430816T DE 69430816 D1 DE69430816 D1 DE 69430816D1
Authority
DE
Germany
Prior art keywords
schizophrenia
treatment
piperidine derivatives
mammal
sulphur
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69430816T
Other languages
English (en)
Other versions
DE69430816T2 (de
Inventor
Porter Bymaster
E Shannon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of DE69430816D1 publication Critical patent/DE69430816D1/de
Publication of DE69430816T2 publication Critical patent/DE69430816T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE69430816T 1993-08-19 1994-08-15 Verwendung von Piperidin-Derivaten in der Behandlung von Schizophrenie Expired - Lifetime DE69430816T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10930093A 1993-08-19 1993-08-19
PCT/DK1994/000305 WO1995005174A1 (en) 1993-08-19 1994-08-15 Antipsychotic method

Publications (2)

Publication Number Publication Date
DE69430816D1 true DE69430816D1 (de) 2002-07-18
DE69430816T2 DE69430816T2 (de) 2002-12-19

Family

ID=22326932

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69430816T Expired - Lifetime DE69430816T2 (de) 1993-08-19 1994-08-15 Verwendung von Piperidin-Derivaten in der Behandlung von Schizophrenie

Country Status (23)

Country Link
EP (1) EP0734259B1 (de)
JP (1) JP3126736B2 (de)
KR (1) KR100360575B1 (de)
CN (1) CN1087936C (de)
AT (1) ATE218864T1 (de)
AU (1) AU701292B2 (de)
CA (1) CA2169839C (de)
CZ (1) CZ285030B6 (de)
DE (1) DE69430816T2 (de)
DK (1) DK0734259T3 (de)
ES (1) ES2177581T3 (de)
FI (2) FI960747A (de)
HU (1) HU221729B1 (de)
IL (1) IL110708A (de)
NO (1) NO312706B1 (de)
NZ (2) NZ271311A (de)
PT (1) PT734259E (de)
RU (1) RU2191580C2 (de)
SG (1) SG55071A1 (de)
TW (1) TW442284B (de)
UA (1) UA63876C2 (de)
WO (1) WO1995005174A1 (de)
ZA (1) ZA946324B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605908A (en) * 1994-10-24 1997-02-25 Eli Lilly And Company Heterocyclic compounds and their use
US5929247A (en) * 1994-10-24 1999-07-27 Eli Lilly And Company Heterocyclic compounds and their preparation and use
US5998404A (en) * 1994-10-24 1999-12-07 Eli Lilly And Company Heterocyclic compounds and their use
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
US5488056A (en) * 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety
CA2202776A1 (en) * 1994-10-31 1996-05-09 Franklin Porter Bymaster Method for treating anxiety
US5726193A (en) * 1994-10-31 1998-03-10 Eli Lilly And Company Method for treating anxiety
US5565475A (en) * 1994-11-08 1996-10-15 Muhlhauser; Mark A. Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
US5763457A (en) * 1995-11-13 1998-06-09 Eli Lilly And Company Method for treating anxiety
US5852037A (en) * 1995-11-13 1998-12-22 Eli Lilly And Company Method for treating anxiety
PT821955E (pt) * 1996-08-01 2002-07-31 Lilly Co Eli Uso de 3-(4-hexiloxi-1,2,5-tiadiazol-3-il)-1,2,5,6-tetrahidro-1-metilpiridina (xanomelina) para o tratamento da doenca bipolar
EP0821957A3 (de) * 1996-08-01 1998-04-22 Eli Lilly And Company Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von Drogenmissbrauch
US6090829A (en) * 1996-08-01 2000-07-18 Eli Lilly And Company Method for treating excessive aggression
EP0821958A3 (de) * 1996-08-01 1998-07-08 Eli Lilly And Company Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von übermässiger Streitsucht
EP0821954A1 (de) * 1996-08-01 1998-02-04 Eli Lilly And Company Verfahren zur Behandlung von geistiger Zurückgebliebenheit
US6043258A (en) * 1996-08-01 2000-03-28 Eli Lilly And Company Method for treating disruptive behavior disorders with xanomeline
US6117890A (en) * 1996-08-01 2000-09-12 Eli Lilly And Company Method for treating bipolar disorder
EP0821959A3 (de) * 1996-08-01 1998-09-16 Eli Lilly And Company Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin zur Behandlung von Nikotin-Entzug
EP0821956A1 (de) * 1996-08-01 1998-02-04 Eli Lilly And Company Verfahren zur Behandlung disruptiver Verhaltensstörungen
US6297262B1 (en) 1997-05-29 2001-10-02 H. Lundbeck A/S Treatment of schizophrenia and psychosis
US6034108A (en) * 1997-07-28 2000-03-07 Eli Lilly And Company Method for treating mental retardation
JP2012533621A (ja) 2009-07-22 2012-12-27 ピュアテック ベンチャーズ ムスカリン性受容体活性化によって改善される疾患の治療のための方法および組成物
CN112789042A (zh) 2018-09-28 2021-05-11 卡鲁娜治疗学有限公司 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法
WO2021097427A1 (en) 2019-11-15 2021-05-20 Karuna Therapeutics, Inc. Xanomeline derivatives and methods for treating neurological disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225999A (en) * 1987-09-10 1992-04-28 Merck Sharp & Dohme Azacyclic- or azabicyclic-substituted thiadiazole derivatives and pharmaceutical compositions
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
DK198490D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
DK198390D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse

Also Published As

Publication number Publication date
EP0734259A1 (de) 1996-10-02
IL110708A0 (en) 1994-11-11
HU221729B1 (hu) 2002-12-28
HU9600364D0 (en) 1996-04-29
CN1087936C (zh) 2002-07-24
FI20050461A (fi) 2005-04-29
KR960703592A (ko) 1996-08-31
DK0734259T3 (da) 2002-09-30
CZ42696A3 (en) 1996-11-13
CA2169839A1 (en) 1995-02-23
CN1133008A (zh) 1996-10-09
NO312706B1 (no) 2002-06-24
ES2177581T3 (es) 2002-12-16
NZ271311A (en) 1999-09-29
CA2169839C (en) 2002-06-11
SG55071A1 (en) 1998-12-21
ZA946324B (en) 1996-02-19
KR100360575B1 (ko) 2003-03-10
NO960619L (no) 1996-04-18
PT734259E (pt) 2002-11-29
EP0734259B1 (de) 2002-06-12
CZ285030B6 (cs) 1999-05-12
UA63876C2 (en) 2004-02-16
JPH09501658A (ja) 1997-02-18
WO1995005174A1 (en) 1995-02-23
TW442284B (en) 2001-06-23
JP3126736B2 (ja) 2001-01-22
FI960747A0 (fi) 1996-02-19
AU701292B2 (en) 1999-01-21
NO960619D0 (no) 1996-02-16
AU7490294A (en) 1995-03-14
FI960747A (fi) 1996-04-17
ATE218864T1 (de) 2002-06-15
IL110708A (en) 1998-12-06
HUT75111A (en) 1997-04-28
RU2191580C2 (ru) 2002-10-27
NZ336597A (en) 2001-02-23
DE69430816T2 (de) 2002-12-19

Similar Documents

Publication Publication Date Title
ATE218864T1 (de) Verwendung von piperidin-derivaten in der behandlung von schizophrenie
DE69523350D1 (de) Behandlung von hyperproliferativen Gefässerkrankungen
DE69729946D1 (de) Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia
ATE150308T1 (de) Hemmung von thrombin
ATE131166T1 (de) Pyranderivate zur verwendung als 5- lipoxygenasehemmer.
EP0604641A4 (de) Zusammensetzung, die aminderivate oder aminverwandte derivate der benzoesäure enthält, und ihre verwendung einschliesslich der behandlung von entzündlichen erkrankungen.
ATE112681T1 (de) Verwendung von benzimidazol-derivaten bei der behandlung von epithelialen erkrankungen.
ATE169217T1 (de) Verwendung von furanonderivaten zur vorbeugung oder behandlung von autoimmunkrankheiten
DE69418744T2 (de) Verwendung von Pregnanderivaten zur Behandlung von Tumoren
ATE212845T1 (de) Verwendung von cytochrome - p 450 - inhibitoren zur hemmung des stoffwechsels von stickstoffsubstituierten acridinen
DE59403966D1 (de) Hydroxymethylfurazancarbonsäurederivate und ihre verwendung in der behandlung von kardiovaskulären erkrankungen
DE68903907D1 (de) Cyclisches peptid, seine herstellung und seine verwendung zur behandlung von cardiovasculaeren stoerungen.
NO20003481L (no) FremgangsmÕte for behandling av COPD
ATE118209T1 (de) Pyridin-3-percarboxylsäure monopersulfat.
DE69619088T2 (de) Quinoxalin-Derivate zur Behandlung von Tinnitus
DE59504374D1 (de) Verwendung von Deoxyspergualin zur Herstellung eines Arzneimittels zur Behandlung von entzündlich-hyperreaktiven Erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ELI LILLY AND CO., INDIANAPOLIS, IND., US

8328 Change in the person/name/address of the agent

Representative=s name: SPOTT, WEINMILLER & BOEHM, 80336 MUENCHEN

8327 Change in the person/name/address of the patent owner

Owner name: NOVO NORDISK A/S, BAGSVAERD, DK